Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Hatano, Manabu ^a,b   Kuwashima, Naruo ^a   Tatsumi, Tomohide ^a   Dusak, Jill E ^a,b   Nishimura, Fumihiko ^a,b   Reilly, Karlyne M ^c   Storkus, Walter J ^a   Okada, Hideho ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccines; Dendritic cells; EphA2; Melanoma

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; EPHRIN RECEPTOR A2; EPITOPE; OVALBUMIN; SYNTHETIC PEPTIDE; TYROSINE KINASE RECEPTOR;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CANCER IMMUNIZATION; CANCER PREVENTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; DRUG TARGETING; FEMALE; GENE TARGETING; GLIOMA CELL; IMMUNITY; LUNG METASTASIS; MELANOMA; MELANOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PROTEIN EXPRESSION; SARCOMA; SARCOMA CELL; SPLEEN CELL; T LYMPHOCYTE; TARGET CELL; TUMOR GROWTH; VASCULAR ENDOTHELIUM;

EID: 18144402083     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-40     Document Type: Article

References (22)

1. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000, 19: 6043-6052.
2. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001, 61:2301-2306.
3. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J: Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002, 21:7011-7026.
4. Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC: Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression. Cancer Res 1995, 55:2528-2532.
5. Easty DJ, Hill SP, Hsu MY, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC: Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer 1999, 84:494-501.
6. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999, 41: 275-280.
7. Zantek ND, Walker-Daniels J, Stewart J, Hansen RK, Robinson D, Miao H, Wang B, Kung HJ, Bissell MJ, Kinch MS: MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 2001, 7:3640-3648.
8. D'Amico TA, Aloia TA, Moore MB, Conlon DH, Herndon JE, Kinch MS, Harpole DHJ: Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 2001, 72: 1144-1148.
9. Dodelet VC, Pasquale EB: Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene 2000, 19: 5614-5619.
10. Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS, Ranieri E, Storkus WJ: Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003, 63:4481-4489.
11. Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K: EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 2003, 63:8476-8480.
12. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T: Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000, 26:109-113.
13. Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows KW, Lotze MT, Chambers WH, Bozik ME: Bone marrow derived dendritic cells pulsed with a tumor specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 1998, 78:196-201.
14. Kuttler C, Nussbaum AK, Dick TP, Rammensee HG, Schild H, Hadeler KP: An algorithm for the prediction of proteasomal cleavages [published erratum appears in J Mol Biol 2000 Aug 4;301(1):229]. J Mol Biol 2000, 298:417-429.
15. Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H: Identification of a novel HLA-A*0201 restricted cytotoxic T lymphocyte epitope in a human glioma associated antigen, interleukin-13 receptor 2 chain. Clin Cancer Res 2002, 8:2851-2855.
16. Nakahara N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H: Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther 2003, 10:549-558.
17. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR: A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992, 67:519-528.
18. Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF: Delivery of Interferonalpha Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines. Cancer Res 2004, 64:5830-5838.
19. Rafii S: Vaccination against tumor neovascularization: Promise and reality. Cancer Cell 2002, 2:429-431.
20. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002, 8:1369-1375.
21. Cheng N, Brantley DM, Liu H, Lin Q, Enriquez M, Gale N, Yancopoulos G, Cerretti DP, Daniel TO, Chen J: Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 2002, 1: 2-11.
22. Dobrzanski MJ, Reome JB, Hollenbaugh JA, Hylind JC, Dutton RW: Effector Cell-Derived Lymphotoxin alpha and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases. Cancer Res 2004, 64: 406-414.